drugset / Trial / NCT05126472
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Phase 1
Recruiting
55 enrolled
Memorial Sloan Kettering Cancer Center
Pin Down Bladder Cancer Research Foundation · collabRockefeller University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have the standard surgical procedure to remove the bladder. The researchers will test different doses of 2141-V11 to see which dose is safest in people. The researchers will also do tests to see how the body absorbs, distributes, and gets rid of 2141-V11. This study is one of the first to test 2141-V11 in people, and the first to test 2141-V11 delivered through a catheter into the bladder.
Timeline
- Start
- 2021-11-08
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2141-V11 | Monoclonal antibody | 10 mg | Intravenous |